BCL2L12 and acute myeloid leukemia: Cellular function indicated miR-182-5p inhibition in AML cells could decrease cell proliferation, promote AML cell apoptosis, and reverse cisplatin (DDP) resistance via targeting BCL2L12 and BCL2 expression [40].